Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017096276) ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/096276 International Application No.: PCT/US2016/064786
Publication Date: 08.06.2017 International Filing Date: 02.12.2016
IPC:
A61K 35/17 (2015.01) ,A61K 39/00 (2006.01) ,A61K 39/395 (2006.01) ,A61K 45/06 (2006.01) ,A61P 31/12 (2006.01) ,A61P 35/00 (2006.01)
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
AGENUS INC. [US/US]; 3 Forbes Road Lexington, Massachusetts 02421, US
MEMORIAL SLOAN-KETTERING CANCER CENTER [US/US]; 1275 York Avenue New York, New York 10065, US
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. [CH/CH]; Stadelhoferstrasse 22 8001 Zurich, CH
Inventors:
WILSON, Nicholas S.; US
WAIGHT, Jeremy D.; US
RITTER, Gerd; US
TSUJI, Takemasa; US
LÉGER, Olivier; FR
SEIBERT, Volker; DE
SCHAER, David; US
MERGHOUB, Taha; US
UNDERWOOD, Dennis J.; US
GONZALEZ, Ana M.; US
VAN DIJK, Marc; NL
Agent:
STEFFE, Eric K.; US
BEZOS, Salvador M.; US
CALVO, Paul A.; US
CIMBALA, Michelle A.; US
COLLER III, Richard D.; US
CORNWELL, David K.S.; US
COVERT, John M.; US
DURKIN, Tracy-Gene G.; US
EISENBERG, Jason D.; US
ELLISON, Eldora L.; US
ESMOND, Robert W.; US
FEATHERSTONE, Donald J.; US
FRUEAUF, Jeremiah B.; US
GOLDSTEIN, Jorge A.; US
GORDON, Lori A.; US
HELVEY, Jeffrey T.; US
HICKS, Ross; US
HOLOUBEK, Michelle K.; US
HOOVER, Kenley K.; US
JACKMAN, Peter A.; US
KIM, Ji-Eun; US
LEE, Michael Q.; US
LONGSWORTH, Gaby L.; US
MCGROARTY, John P.; US
MESSINGER, Michael V.; US
MILLONIG, Robert C.; US
MUTSCHELKNAUS, Joseph; US
NANNENGA-COMBS, Bonnie; US
PICKARD, Byron L.; US
RAY, Michael B.; US
ROSE GILLENTINE, Marsha; US
RYGIEL, Mark W.; US
SHEA, JR., Timothy J.; US
SOKOHL, Robert E.; US
SPECHT, Michael D.; US
STERLING, Deborah A.; US
STERNE, Robert Greene; US
TUMINARO, Jonathan; US
WRIGHT, Jon E.; US
Priority Data:
62/262,37502.12.2015US
Title (EN) ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF
(FR) ANTICORPS ANTI-GITR ET PROCÉDÉS D'UTILISATION ASSOCIÉS
Abstract:
(EN) The present disclosure provides antagonist antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., reduce, deactivate, or inhibit GITR activity. The present disclosure also provides methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human GITR and modulates GITR activity, e.g., reduces, deactivates, or inhibits GITR activity.
(FR) La présente invention concerne des anticorps antagonistes qui se lient spécifiquement au récepteur apparenté à la famille du TNFR induit par les glucocorticoïdes (GITR) humain et des compositions comprenant ces anticorps. Selon un aspect spécifique, les anticorps se lient spécifiquement au GITR humain et modulent l'activité du GITR, par exemple, réduisent, désactivent ou inhibent l'activité du GITR. La présente invention concerne également des procédés de traitement de maladies ou de troubles auto-immuns ou inflammatoires, par administration d'un anticorps qui se lie spécifiquement au GITR humain et module l'activité du GITR, par exemple, réduit, désactive ou inhibe l'activité du GITR.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)